Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

"Prior studies have shown that Non-Obese Diabetic (NOD) mice became hyperglycemic again a median of 17 days after treatment with syngeneic islet cell transplants," said Mark Berger, Chief Medical Officer at Genprex. "Our recent preclinical studies of Type 1 NOD mouse models treated with GPX-002 have shown durability of glucose control to approximately 120 days, or 4 months. This suggests that that the new insulin producing beta- like cells that our therapy produced are poorly recognized by the autoimmune pr ...